首页> 外文期刊>Health services & outcomes research methodology >Novel statistical approaches and applications in leveraging real-world data in regulatory clinical studies
【24h】

Novel statistical approaches and applications in leveraging real-world data in regulatory clinical studies

机译:在监管临床研究中利用现实世界数据的新型统计方法和应用

获取原文
获取原文并翻译 | 示例
           

摘要

In medical product development, there has been a growing interest in utilizing real-world data which have become abundant owing to advances in biomedical science, information technology and engineering. High-quality real-world data may be utilized to generate real-world evidence for regulatory or healthcare decision-making. We discuss propensity score-based approaches for leveraging patients from a real-world data source to construct a control group for a non-randomized comparative study or to augment a single-arm or randomized prospective investigational clinical study. The proposed propensity score-based approaches leverage real-world patients that are similar to those prospectively enrolled into the investigational clinical study in terms of baseline characteristics. Either frequentist or Bayesian inference can then be applied for outcome data analysis, with the option of down-weighting information from the real-world data source. Examples based on pre-market regulatory review experience are provided to illustrate the implementation of the proposed approaches.
机译:在医疗产品开发中,人们对利用真实世界的数据越来越感兴趣,由于生物医学、信息技术和工程的进步,这些数据变得越来越丰富。高质量的真实世界数据可用于生成监管或医疗决策的真实世界证据。我们讨论了基于倾向评分的方法,以利用来自真实世界数据源的患者,为非随机对照研究或增加单臂或随机前瞻性临床研究构建对照组。建议的基于倾向评分的方法利用了现实世界中的患者,这些患者在基线特征方面与前瞻性纳入研究性临床研究的患者相似。然后,无论是频繁推理还是贝叶斯推理都可以应用于结果数据分析,可以选择对来自真实数据源的信息进行降权。本文提供了基于上市前监管审查经验的示例,以说明拟议方法的实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号